<![CDATA[Iksuda Therapeutics 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=36091>Tue, 21 Apr 2026 22:13:36 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Iksuda Presents Encouraging IKS014 Phase 1 Data at ESMO]]>https://www.newswire.co.kr/newsRead.php?no=1020955Mon, 20 Oct 2025 15:07:34 +0900<![CDATA[Iksuda Therapeutics announces first patient dosed in Phase 1 trial of IKS014 in patients with advanced solid tumours that express HER2]]>https://www.newswire.co.kr/newsRead.php?no=977023Tue, 24 Oct 2023 16:25:00 +0900<![CDATA[익수다 테라퓨틱스, HER2 발현 진행성 고형종양 환자 대상 IKS014 임상 1상 시험에서 첫 환자 투약 발표]]>https://www.newswire.co.kr/newsRead.php?no=977024Tue, 24 Oct 2023 16:25:00 +0900<![CDATA[Iksuda Therapeutics Deepens Clinical Pipeline Through Licensing Agreement for Her2 Antibody Drug Conjugate Programme From LegoChem Biosciences]]>https://www.newswire.co.kr/newsRead.php?no=937860Mon, 10 Jan 2022 17:30:00 +0900<![CDATA[익수다 테라퓨틱스, 레고켐 바이오사이언스와 라이선스 계약으로 임상 파이프라인 강화]]>https://www.newswire.co.kr/newsRead.php?no=937861Mon, 10 Jan 2022 17:30:00 +0900<![CDATA[LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates]]>https://www.newswire.co.kr/newsRead.php?no=925808Wed, 23 Jun 2021 11:45:00 +0900<![CDATA[레고켐 바이오사이언스와 익수다 테라퓨틱스, 항체-약물 접합체 개발 위한 라이선스 계약 확대]]>https://www.newswire.co.kr/newsRead.php?no=925809Wed, 23 Jun 2021 11:45:00 +0900<![CDATA[Iksuda Therapeutics Closes $47 Million Financing Round]]>https://www.newswire.co.kr/newsRead.php?no=924883Tue, 08 Jun 2021 10:30:00 +0900<![CDATA[익수다 테라퓨틱스, 4700만달러 투자 유치]]>https://www.newswire.co.kr/newsRead.php?no=924884Tue, 08 Jun 2021 10:30:00 +0900<![CDATA[Iksuda Therapeutics Enters License Agreement With University of Goettingen to Develop a New Generation of Antibody Drug Conjugates]]>https://www.newswire.co.kr/newsRead.php?no=912122Wed, 14 Oct 2020 13:30:00 +0900<![CDATA[익수다 테라퓨틱스, 차세대 항체-약물 복합체 개발 위해 괴팅겐대학교와 라이선스 계약 체결]]>https://www.newswire.co.kr/newsRead.php?no=912123Wed, 14 Oct 2020 13:30:00 +0900